» Articles » PMID: 23989652

Epidemiology of Chagas Disease in Europe: Many Calculations, Little Knowledge

Overview
Date 2013 Aug 31
PMID 23989652
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Chagas disease and its causative agent Trypanosoma cruzi are endemic in almost all countries in South and Middle America. Currently, there are more than 10 million affected people. It is the most common reason for heart failure and a frequent cause of intestinal problems in Latin America. The phenotype of the Chagas cardiomyopathy is varying. Dilative cardiomyopathy, often accompanied by an apical aneurysm is the most common finding in the end stage heart failure, but rhythm disorders like conduction blocks, ventricular or supraventricular forms of tachycardia or repolarization changes occur as well, mainly in the early stages. Migration of infected people leads to a distribution from the endemic countries to North America and Europe. Although more than 500,000 people of Latin American origin are currently living in Europe, Chagas disease is not considered as a public health problem, yet. Cases of transmission via blood donation, organ transplantation or from mother-to-child are reported for several European countries but there is no database for Germany. Current epidemiological data are mostly available from regional surveys from other countries or are extrapolated. Hence, there is a large variation in the estimated numbers on the incidence of Chagas. Robust and reliable data are lacking. This review gives an overview on the currently available data and calls for a German Chagas surveillance.

Citing Articles

Mechanisms behind the high mortality rate in chronic Chagas cardiomyopathy: Unmasking a three-headed monster.

Echeverria L, Serrano-Garcia A, Rojas L, Berrios-Barcenas E, Gomez-Mesa J, Gomez-Ochoa S Eur J Heart Fail. 2024; 26(12):2502-2514.

PMID: 39327798 PMC: 11683869. DOI: 10.1002/ejhf.3460.


Cyclodextrin Complexes for the Treatment of Chagas Disease: A Literature Review.

Taio F, Converti A, Lima A Int J Mol Sci. 2024; 25(17).

PMID: 39273458 PMC: 11395308. DOI: 10.3390/ijms25179511.


Prevention of congenital chagas disease by trypanocide treatment in women of reproductive age: A meta-analysis of observational studies.

de Moraes F, Cavalcanti Souza M, Moro L, Donadon I, DA Silva E, Souza D PLoS Negl Trop Dis. 2024; 18(9):e0012407.

PMID: 39236037 PMC: 11376591. DOI: 10.1371/journal.pntd.0012407.


Chagas Disease in Europe.

Gonzalez-Sanz M, Crespillo-Andujar C, Chamorro-Tojeiro S, Monge-Maillo B, Perez-Molina J, Norman F Trop Med Infect Dis. 2023; 8(12).

PMID: 38133445 PMC: 10747626. DOI: 10.3390/tropicalmed8120513.


Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies.

Muraca G, Ruiz M, Gambaro R, Scioli-Montoto S, Sbaraglini M, Padula G Beilstein J Nanotechnol. 2023; 14:804-818.

PMID: 37533841 PMC: 10390827. DOI: 10.3762/bjnano.14.66.


References
1.
Davila D, Angel F, Arata de Bellabarba G, Donis J . Effects of metoprolol in chagasic patients with severe congestive heart failure. Int J Cardiol. 2002; 85(2-3):255-60. DOI: 10.1016/s0167-5273(02)00181-x. View

2.
Andrade Z . Immunopathology of Chagas disease. Mem Inst Oswaldo Cruz. 2000; 94 Suppl 1:71-80. DOI: 10.1590/s0074-02761999000700007. View

3.
Marin-Neto J, Rassi Jr A, Avezum Jr A, Mattos A, Rassi A, Morillo C . The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz. 2009; 104 Suppl 1:319-24. DOI: 10.1590/s0074-02762009000900042. View

4.
Rassi Jr A, Rassi A, Marin-Neto J . Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem Inst Oswaldo Cruz. 2009; 104 Suppl 1:152-8. DOI: 10.1590/s0074-02762009000900021. View

5.
Wendel S . Transfusion-transmitted Chagas' disease. Curr Opin Hematol. 1998; 5(6):406-11. DOI: 10.1097/00062752-199811000-00009. View